Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

NCT00047502 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG: Lonafarnib (SCH66336)
DRUG: Imatinib Mesylate (Gleevec)

Sponsor

M.D. Anderson Cancer Center